Valuation: Jupiter Neurosciences, Inc.

Market Cap 2M 1.83M 1.69M 1.53M 2.87M 187M 2.99M 20.41M 8.07M 101M 7.52M 7.36M 319M P/E 2024
-126x
P/E 2025 -4.08x
Enterprise Value 3.53M 3.22M 2.98M 2.69M 5.07M 330M 5.26M 35.99M 14.23M 178M 13.26M 12.98M 563M EV / Sales 2024
-
EV / Sales 2025 1,681x
Free-Float
69.36%
Yield 2024 *
-
Yield 2025 -
1 day+3.62%
1 week-15.32%
Current month-23.17%
1 month-42.73%
3 months-67.19%
6 months-93.44%
Current year-97.94%
1 week 1.37
Extreme 1.37
1.9
1 month 1.37
Extreme 1.37
3.24
Current year 1.37
Extreme 1.37
81.75
1 year 1.37
Extreme 1.37
101.25
3 years 1.37
Extreme 1.37
1,463.25
5 years 1.37
Extreme 1.37
1,463.25
10 years 1.37
Extreme 1.37
1,463.25
Manager TitleAgeSince
Chief Administrative Officer 34 01/01/2016
Chief Tech/Sci/R&D Officer 71 01/01/2016
Chief Executive Officer 74 01/01/2016
Director TitleAgeSince
Chairman 74 01/01/2016
Director/Board Member 71 01/01/2016
Director/Board Member 48 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/26 Free

Director

472,222 0.9792%
29/06/26 Free

Director

536,428 1.1124%
02/06/26 Free

Director

100,000 0.2756%
Change 5-day change 1-year change 3-year change Capi.($)
+3.62%-15.32%-98.38% - 2M
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.14%-3.20%+7.62%+90.41% 58.93B
+0.06%+0.15%+25.94%+86.73% 55.21B
-0.57%-3.13%+13.90%+114.48% 46.1B
-1.79%-6.18%+16.96%+23.90% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
+0.76%-8.19%+129.56%+645.10% 34.57B
+0.03%-0.93%+76.71%+57.52% 32.46B
+18.08%+20.18%-30.29%+476.36% 26.28B
Average +2.50%-5.54%+22.12%+178.89% 40B
Weighted average by Cap. +1.50%-2.69%+35.05%+149.28%

Financials

2024 2025
Net sales - 21.8K 19.88K 18.38K 16.59K 31.24K 2.04M 32.47K 222K 87.74K 1.1M 81.77K 80.06K 3.47M
Net income -2.44M -2.22M -2.06M -1.86M -3.5M -228M -3.63M -24.85M -9.82M -123M -9.15M -8.96M -389M -8.64M -7.88M -7.29M -6.58M -12.39M -808M -12.88M -88.04M -34.8M -436M -32.43M -31.75M -1.38B
Net Debt -3.55M -3.24M -2.99M -2.7M -5.09M -332M -5.29M -36.17M -14.3M -179M -13.32M -13.05M -566M 1.53M 1.4M 1.29M 1.16M 2.19M 143M 2.28M 15.58M 6.16M 77.17M 5.74M 5.62M 244M
Projected Income Statement - Annual - Jupiter Neurosciences, Inc.
Logo Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The Company's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The Company's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. It is also focused on a Phase IIa clinical study in Parkinson's disease. It also has rights in ALA-002.
Employees
-
Date Price Change Volume
19/11/26 $1.575 +3.62% 3,441
18/11/26 $1.520 0.00% 14,938
17/11/26 $1.520 -10.59% 11,266
16/11/26 $1.700 -3.41% 11,820
13/11/26 $1.760 -5.38% 12,564

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Jupiter Neurosciences, Inc.
  1. Stock Market
  2. Stocks
  3. JUNS Stock